Skip to main content

Table 6 Levels and reducing percentage of LDL-C, dosage and duration in different statin group in Western and Asian (Mean ± SD)

From: The difference between Asian and Western in the effect of LDL-C lowering therapy on coronary atherosclerotic plaque: a meta-analysis report

Group N Age MeanLDL-C at baseline (mg) MeanLDL-C at follow up (mg) Mean reducing percentage Statin dosage (mg) Duration (month)
Western Rosuvastatin 869 57.8 ± 0.6 124.2 ± 5.1 61.9 ± 0.9 49.9 ± 2.6 40.0 ± 0.0 24.0 ± 0.0
Atorvastatin 772 57.2 ± 1.0 129.8 ± 14.2 73.1 ± 4.1 43.0 ± 2.1 80.0 ± 0.0 22.0 ± 2.8
Pravastatin 249 56.6 ± 0.0 150.2 ± 0.0 110.4 ± 0.0 25.0 ± 0.0 40.0 ± 0.0 18.0 ± 0.0
Simvastatin 40 57.7 ± 0.0 158.7 ± 0.0 85.1 ± 0.0 46.7 ± 0.0 40.0 ± 0.0 25.0 ± 0.0
Asian Rosuvastatin 304 58.9 ± 3.3 123.1 ± 14.6 67.2 ± 13.8 44.0 ± 4.8 14.1 ± 4.9 10.3 ± 3.7
Atorvastatin 366 60.9 ± 3.0 124.1 ± 12.7 72.9 ± 14.2 40.7 ± 5.5 18.9 ± 2.9 7.8 ± 2.2
Pitavastatin 125 62.5 ± 11.5 130.9 ± 33.3 81.1 ± 23.4 36.2 ± 19.5 4 8 ~ 12
Pravastatin 70 64.0 ± 1.8 134.9 ± 8.4 130.5 ± 0.9 23.1 ± 5.3 16.3 ± 2.2 6.0 ± 0.0
Fluvastatin 40 63.0 ± 10.0 144.9 ± 31.5 98.1 ± 12.7 32.3 60 12
Simvastatin 50 58.0 ± 0.0 119.0 ± 0.0 78.0 ± 0.0 34.5 ± 0.0 20.0 ± 0.0 12.0 ± 0.0
\